Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

M. Stone, Richard; J. Mandrekar, Sumithra; L. Sanford, Ben; Laumann, Kristina; M. Geyer, Susan; D. Bloomfield, Clara; Thiede, Christian; W. Prior, Thomas; Döhner, Konstanze; Marcucci, Guido; Lo‐Coco, Francesco; B. Klisovic, Rebecca; H. Wei, Andrew; Sierra, Jorge; Á. Sanz, Miguel; Brandwein, Joseph; de Witte, Théo; Niederwieser, Dietger; R. Appelbaum, Frederick; C. Medeiros, Bruno; S. Tallman, Martin; Krauter, Jürgen; F. Schlenk, Richard; Ganser, Arnold; Serve, Hubert; Ehninger, Gerhard; Amadori, Sergio; A. Larson, Richard; Döhner, Hartmut

doi:10.1056/nejmoa1614359

Public

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Published in New England Journal of Medicine • Jun 23, 2017

Authors:

Richard M. Stone

Sumithra J. Mandrekar

Ben L. Sanford

Abstract

BACKGROUND: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolo...

Subject

Midostaurin

Medicine

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!